Skip to main content

Plavix Disease Interactions

There are 3 disease interactions with Plavix (clopidogrel).

Major

Clopidogrel (applies to Plavix) bleeding

Major Potential Hazard, Moderate plausibility.

Clopidogrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.

Switch to professional interaction data

Moderate

Clopidogrel (applies to Plavix) liver disease

Moderate Potential Hazard, Moderate plausibility.

The pharmacokinetic disposition of clopidogrel in patients with liver disease has not been established. Clopidogrel undergoes biotransformation to an active metabolite that has not yet been isolated and an inactive form that represents approximately 85% of circulating clopidogrel. The metabolic and therapeutic activity of clopidogrel may be altered in patients with hepatic impairment and should be administered cautiously in patients with severe hepatic dysfunction. Clinical monitoring of hepatic function and bleeding activity is recommended.

Switch to professional interaction data

Minor

Clopidogrel (applies to Plavix) renal dysfunction

Minor Potential Hazard, Low plausibility.

Clopidogrel is partially eliminated by the kidney. Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces. Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min). However, bleeding times in patients with severe renal impairment did not differ from those with normal renal function. No dosage adjustment is recommended for patients with compromised renal function.

Switch to professional interaction data

Plavix drug interactions

There are 273 drug interactions with Plavix (clopidogrel).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer